Sponsor Pipeline

Regor Pharmaceuticals Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
4
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-13 NCT05304962
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative…		 date change Primary completion pushed: 2026-09-30 -> 2026-12-30
2026-08-13 NCT05304962
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative…		 date change Completion pushed: 2026-12-30 -> 2027-03-31
Active Trials by Phase
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT07524322 Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors Breast Cancer Recruiting
NCT05304962 FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative… Breast Cancer Recruiting
NCT06299124 A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast… Breast Cancer Active, Not Recruiting
Disease Areas
Breast Cancer (3) Ovarian Cancer (1) Cervical Cancer (1) Endometrial Cancer (1)
Get alerts when Regor Pharmaceuticals Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free